Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure

NCT04311697 is registered in ClinicalTrials.gov with APR Applied Pharma Research s.a. as lead sponsor.

NCT NCT04311697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04311697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ZYESAMI (Aviptadil) for the Treatment of Critical COVID-19 With Respiratory Failure
Lead sponsor
APR Applied Pharma Research s.a.
Phase
Phase 2/3
Overall status
Completed
Start date
May 15, 2020
Completion date
February 22, 2021
Enrollment
203 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, acute respiratory distress syndrome (ards), corona virus infection, critical covid-19 with respiratory failure